Christine Shaw, VP, Assay Development at GenMark Diagnostics, Inc. (GNMK), sold 6,302 shares at $17.03 ($107K) on 2021-02-26, disclosed to the SEC on 2021-03-01.
Open-market sale of $107k GNMK by VP, Assay Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.03 | 3,151 | $54K | 50.0% |
| 2 | $17.03 | 3,151 | $54K | 50.0% |
| Total | $17.03 avg | 6,302 | $107K | 100% |
| Filing → |
| GNMK | SELL | 2021-01-29 | $1K | — | Filing → |
| GNMK | SELL | 2020-12-09 | $4K | — | Filing → |
| GNMK | SELL | 2020-11-25 | $5K | — | Filing → |